MiNK Therapeutics Cuts Q2 Cash Use 31%

MiNK Therapeutics (NASDAQ:INKT), a biotechnology company developing therapies using invariant natural killer T (iNKT) cells for cancer and immune diseases, issued its second quarter results on August 14, 2025. The most notable headline was a net loss per share of $1.06 (GAAP). No revenue was reported, as expected for a clinical-stage firm. Cash used in operations (GAAP) improved to $1.57 million, while the company shored up its liquidity post-quarter, raising $13 million through equity sales after the period. Overall, while the period saw clinical progress and an improved operational cash use, the miss on earnings expectations and ongoing losses stood out. Source: Analyst estimates for the quarter provided by FactSet. MiNK Therapeutics is working to deliver off-the-shelf cell therapies using iNKT cells—a type of immune cell with both adaptive and innate characteristics. These cells are designed to target cancerous tumors and severe immune disorders in a way that harnesses both rapid action and memory for future immune responses.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool